The role of human defensins in gastrointestinal diseases

Expert Review of Clinical Immunology

Volumn 7, Issue 6, 2011, Pages 779-787

  Langhorst, Jost ^a   Choi, Kyung Eun ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

bacteria; Crohn's disease; defensins; gastrointestinal infections; HBD; HD; innate immunity; irritable bowel syndrome; NOD2; ulcerative colitis

Indexed keywords

BIOLOGICAL MARKER; DEFENSIN;

ADAPTIVE IMMUNITY; ENTERITIS; GASTROINTESTINAL DISEASE; HUMAN; IMMUNOPATHOGENESIS; INNATE IMMUNITY; IRRITABLE COLON; REVIEW;

BIOLOGICAL MARKERS; DEFENSINS; HUMANS; IMMUNITY, INNATE; INFLAMMATORY BOWEL DISEASES; IRRITABLE BOWEL SYNDROME;

EID: 80054907581     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/eci.11.62     Document Type: Review

References (79)

1. Wehkamp J, Schauber J, Stange EF. Defensins and cathelicidins in gastrointestinal infections. Curr. Opin. Gastroenterol. 23, 32-38 (2007)
2. Ramasundara M, Leach ST, Lemberg DA, Day AS. Defensins and inflammation: the role of defensins in inflammatory bowel disease. J. Gastroenterol. Hepatol. 24, 202-208 (2009)
3. Wehkamp J, Stange EF. Paneth's disease. J. Crohn's Colitis 4, 523-531 (2010)
4. Wehkamp J, Stange EF, Fellerman K. Defensin-immunology in inflammatory bowel disease. Gastroenterol. Clin. Biol. 33(Suppl. 3), 137-144 (2009)
5. Wehkamp J, Fellerman K, Herrlinger KR, et al. Human β-defensin 2 but not β-defensin 1 is expressed preferentially in colonic mucosa of inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 14, 745-752 (2002)
6. Fellerman K, Wehkamp J, Herrlinger KR, Stange EF. Crohn's disease: a defensin deficiency syndrome? Eur. J. Gastroenterol. Hepatol. 15, 627-634 (2003)
7. Salzman NH, Underwood MA, Bevins CL. Paneth cells, defensins, and the commensal microbiota: a hypothesis on intimate interplay at the intestinal mucosa. Semin. Immunol. 19, 70-83 (2007)
8. Wehkamp J, Koslowski M, Wang G, Stange EF. Barrier dysfunction due to distinct defensing deficiencies in small intestinal and colonic Crohn's disease. Mucosal Immunol. 1(1), 67-74 (2008)
9. Langhorst J, Junge A, Rueffer A, et al. Elevated human β-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome. Am. J. Gastroenterol. 104, 404-410 (2009)
10. Cunliffe RN. α-defensins in the gastrointestinal tract. Mol. Immunol. 40, 463-467 (2003)
11. Voss E, Wehkamp J, Wehkamp K, Stange EF, Schroder JM, Harder J. NOD2/CARD15 mediates induction of the antimicrobial peptide human β-defensin-2. J. Biol. Chem. 281, 2005-2011 (2006)
12. Wehkamp J, Harder J, Weichenthal M, et al. Inducible and constitutive β-defensins are differentially expressed in Crohn's disease and ulcerative colitis. Inflamm. Bowel Dis. 4, 215-223 (2003)
13. Ouellette AJ, Hsieh MM, Nosek MT, et al. Mouse Paneth cell defensins: primary structures and antibacterial activities of numerous cryptdin isoforms. Infect. Immun. 62, 5040-5047 (1994)
14. Selsted ME, Miller SI, Henschen AH, et al. Enteric defensins: antibioitic peptide components of intestinal host defense. J. Cell. Biol. 118, 929-936 (1992)
15. Harder J, Bartels J, Christophers E, et al. A peptide antibiotic from human skin. Nature 387, 861 (1997)
16. Harder J, Bartels J, Christophers E, et al. Isolation and characterization of human β-defensin-3, a novel human inducible peptide antibiotic. J. Biol. Chem. 276, 5707-5713 (2001)
17. Zasloff M. Antibiotic peptides as mediators of innate immunity. Curr. Opin. Immunol. 4, 3-7 (1992)
18. Wehkamp J, Salzman NH, Porter E, et al. Reduced Paneth cell α-defensins in ileal Crohn's disease. Proc. Natl Acad. Sci. USA 13, 102(50), 18129-18134 (2005)
19. Wehkamp J, Fellerman K, Stange EF. Human defensins in Crohn's Disease. A molecular link to mucosal barrier dysfunction. In: Mechanisms of Epithelial Defense (Volume 86). Kabelitz D, Schröder JM (Eds). Karger, Basel, Switzerland, 42-54 (2005)
20. Schutte BC, Mitros JP, Bartlett JA, et al. Discovery of five conserved β-defensin gene clusters using a computational search strategy. Proc. Natl Acad. Sci. USA 99, 2129-2133 (2002)
21. Wehkamp J, Schmid M, Stange EF. Defensins and other antimicrobial peptides in inflammatory bowel disease. Curr. Opin. Gastroenterol. 23, 370-378 (2007)
22. Ouellette AJ, Bevins CL. Paneth cell defensins and innate immunity of the small bowel. Inflamm. Bowel Dis. 7, 43-50 (2001)
23. Salzman NH, Hung K, Haribhai D, et al. Enteric defensins are essential regulators of intestinal microbial ecology. Nat. Immunol. 11(1), 76-82 (2010)
24. Ayabe T, Satchell DP, Wilson CL, et al. Secretion of microbicidal α-defensins by intestinal Paneth cells in response to bacteria. Nat. Immunol. 2, 113-118 (2000)
25. Zhao C, Wang I, Lehrer RI. Widespread expression of β-defensin hBD-1 in human secretory glands and epithelial cells. FEBS Lett. 396(2-3), 319-322 (1996)
26. Lakatos PL, Altorjay I, Mandi Y, et al. Interaction between seroreactivity to microbial antigens and genetics in Crohn's disease: is there a role for defensins? Tissue Antigens 71, 552-559 (2008)
27. Schroeder BO, Wu Z, Nuding SM, et al. Reduction of disulphide bonds unmasks potent antimicrobial activity of human β-defensin 1. Nature 469, 419-425 (2011)
28. Wehkamp J, Harder J, Wehkamp K, et al. NF-kB and AP-1-mediated induction of human β-defensin-2 in intestinal epithelial cells by Escherichia Coli Nissle 1917: a novel effect of a probiotic bacterium. Infect. Immun. 10, 5750-5758 (2004)
29. Kobayashi T, Okamoto S, Hisamatsu T, et al. IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease. Gut 57(12), 1682-1689 (2008)
30. Frye M, Bargon J, Lembke B, Wagner TO, Gropp R. Differential expression of human a- and β-defensins mRNA in gastrointestinal epithelia. Eur. J. Clin. Invest. 30(8), 695-701 (2000)
31. Langhorst J, Wieder A, Rueffer A, et al. Activated innate immune system in irritable bowel disease? Gut 9, 1325-1326 (2007)
32. O'Neil DA, Porter EM, Elewaut D, et al. Expression and regulation of the human β-defensins hBD-1 and hBD-2 in intestinal epithelium. J. Immunol. 163(12), 6718-6724 (1999)
33. Sellon RK, Tonkonogy S, Schulz M, et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin- 10-deficient mice. Infect. Immun. 66, 5224-5231 (1998)
34. Zilbauer M, Jenke A, Wenzel G, et al. Expression of human β-defensins in children with chronic inflammatory bowel disease. PLoS One 5(10), e15389 (2010)
35. Simms LA, Doecke JD, Walsh MD, Huang N, Fowler EV, Radford-Smith GL. Reduced a-defensin expression is associated with inflammation and not NOD2 mutation status in ileal Crohn's disease. Gut 57, 903-910 (2008)
36. Fellermann K, Stange DE, Schaeffeler E, et al. A chromosome 8 gene-cluster polymorphism with low human β-defensin 2 gene copy number predisposes to Crohn disease of the colon. Am. J. Hum. Genetics 79, 439-448 (2006)
37. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411, 603-606 (2006)
38. Vavricka SR, Rogler G. New insights into the pathogenesis of Crohn's disease: are they relevant for therapeutic options? Swiss Med. Wkly 139(37-38), 527-534 (2009)
39. Barreira-de-Acosta M, Mendoza JL, Lana R, Dominguez-Munoz JE, Diaz-Rubio M. NOD2/CARD15: geographic differences in the Spanish population and clinical applications in Crohn's disease. Rev. Esp. Enferm. Dig. 102(5), 321-326 (2010)
40. Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat. Genet. 40, 955-962 (2008)
41. Franke A, Balschun T, Karlsen TH, et al. Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat. Genet. 40, 1319-1323 (2008)
42. Fisher SA, Tremelling M, Andersen CA, et al. Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease. Nat. Genet. 40, 710-712 (2008)
43. Stallmach A, Carstens O. Role of infections in the manifestation or reactivation of inflammatory bowel diseases. Inflamm. Bowel Dis. 8, 213-218 (2002)
44. Card T, Logan RFA, Rodrigues LC, Wheeler JG. Antiobiotic use and the development of Crohn's disease. Gut 53, 246-250 (2004)
45. Bernstein CN. Epidemiologic clues to inflammatory bowel disease. Curr. Gastroenterol. Rep. 12(6), 495-501 (2010)
46. Salzman NH, Bevins CL. Negative interactions with the microbiota: IBD. Adv. Exp. Med. Biol. 635, 67-78 (2008)
47. Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterol. 122, 44-54 (2002)
48. Nuding S, Fellerman K, Wehkamp J, Stange EF. Reduced mucosal antimicrobial activity in Crohn's disease of the colon. Gut 56, 1240-1247 (2007)
49. Aldhous MC, Noble CL, Satsangi J. Dysregulation of human β-defensin-2 protein in inflammatory bowel disease. PLoS One 4(7), e6285 (2009)
50. Hollox EJ. β-defensins and Crohn's disease: confusion from counting copies. Am. J. Gastroenterol. 105, 360-362 (2010)
51. Kanda N, Watanabe S. IL-12, IL-23, and IL-27 enhance human β-defensin-2 production in human keratinocytes. Eur. J. Immunol. 38(5), 1287-1296 (2008)
52. Kao CY, Chen Y, Thai P, et al. IL-17 markedly up-regulates β-defensin-2 expression in human airway epithelium via JAK and NF-kB signaling pathways. J. Immunol. 173(5), 3482-3491 (2004)
53. Wehkamp J, Chu H, Shen B, et al. Paneth cell antimicrobial peptides: topographical distribution and quantification in human gastrointestinal tissues. FEBS Lett. 580(22), 5344-5350 (2006)
54. Elphick D, Liddell S, Mahida YR. Impaired luminal processing of human defensin-5 in Crohn's disease: persistence in a complex with chymotrypsinogen and trypsin. Am. J. Pathol. 172, 702-713 (2008)
55. Inohara N, Chamaillard M, McDonald C, Nunez G. NOD-LRR proteins: role in host-microbial interactions and inflammatory disease. Annu. Rev. Biochem. 19, 355-383 (2005)
56. Lala S, Ogura Y, Osborne C, et al. Crohn's disease and the NOD2 gene: a role for paneth cells. Gastroenterol. 125, 47-57 (2003)
57. Ogura Y, Lala S, Xin W, et al. Crohn's disease and the NOD2 (CARD15) gene in human intestinal epithelial cells. Gastroenterol. 124, 1001-1009 (2003)
58. Gasche C, Grundtner P. Genotypes and phenotypes in Crohn's disease: do they help in clinical management? Gut 54, 162-174 (2005)
59. Bernard P, Flemin A, Lacombe A, Harley VR, Vilain E. Wnt4 inhibits b-catenin/ TCF signalling by redirecting b-catenin to the cell membrane. Biol. Cell. 100(3), 167-177 (2008)
60. Simms LA, Doecke JD, Roberts RL, et al. KCNN4 gene variant is associated with ileal Crohn's disease in the Australian and New Zealand population. Am. J. Gastroenterol. 105(10), 2209-2217 (2010)
61. Bentley RW, Pearson J, Gearry RB, et al. Association of higher DEFB4 genomic copy number with Crohn's disease. Am. J. Gastroenterol. 105, 354-359 (2010)
62. Fahlgren A, Hammarstrom S, Danielsson A, et al. β-defensin-3 and -4 in intestinal epithelial cells display increased mRNA expression in ulcerative colitis. Clin. Exp. Immunol. 137, 397-385 (2003)
63. Noble CL, Abbas AR, Cornelius J, et al. Regional variation in gene expression in the healthy colon is dysregulated in ulcerative colitis. Gut 57(10), 1398-1405 (2008)
64. Möndel M, Schroeder BO, Zimmermann K, et al. Probiotic E.coli treatment mediates antimicrobial human β-defensin synthesis and fecal excretion in humans. Mucosal Immunol. 2(2), 166-172 (2009)
65. Dinan TG, Quigley EMM, Ahmed SMM, et al. Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterol. 130, 304-311 (2006)
66. Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut 45(Suppl. 2), 43-47 (1999)
67. Spiller RC, Jenkins D, Thornley JP, et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 47, 804-811 (2000)
68. Dunlop SP, Jenkins D, Neal KR, et al. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterol. 125, 1651-1659 (2003)
69. Cumberland P, Sethi D, Roderick PJ, et al. The infectious intestinal disease study of England: a prospective evaluation of symptoms and health care use after an acute episode. Epidemiol. Infect. 130, 453-460 (2003)
70. Gwee KA, Collins SM, Read NW, et al. Increased rectal mucosal expression of interleukin 1b in recently acquired post-infectious irritable bowel syndrome. Gut 52, 523-526 (2003)
71. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am. J. Gastroenterol. 95, 3503-3506 (2000)
72. Gwee K. Post-infectious irritable bowel syndrome, an inflammation- immunological model with relevance for other IBS and functional dyspepsia. J. Neurogastroenterol. Motil. 16(1), 30-34 (2010)
73. Lee KJ, Kim YB, Kim JH, Kwon HC, Kim DK, Cho SW. The alteration of enterochromaffin cell, mast cell, and lamina propria T lymphocyte numbers in irritable bowel syndrome and its relationship with psychological factors. J. Gastroenterol. Hepatol. 23(11), 1689-1694 (2008)
74. Chadwick VS, Chen W, Shu D, et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterol. 122(7), 1778-1783 (2002)
75. Guilarte M, Santos J, de Torres I, et al. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut 56(2), 203-209 (2007)
76. Ohman L, Isaksson S, Lundgren A, Simrén M, Sjövall H. A controlled study of colonic immune activity and b7+ blood T lymphocytes in patients with irritable bowel syndrome. Clin. Gastroenterol. Hepatol. 3(10), 980-986 (2005)
77. Elsenbruch S, Holtmann G, Oezcan D, et al. Are there alterations of neuroendocrine and cellular immune responses to nutrients in women with irritable bowel syndrome? Am. J. Gastroenterol. 99, 703-710 (2004)
78. Gonsalkorale WM, Perrey C, Pravica V, Whorwell PJ, Hutchinson IV. Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component? Gut 52(1), 91-93 (2003)
79. Van der Veek PP, van den Berg M, de Kroon YE, Verspaget HW, Masclee AA. Role of tumor necrosis factor-α and interleukin-10 gene polymorphisms in irritable bowel syndrome. Am. J. Gastroenterol. 100(11), 2510-2516 (2005)